Plural Carboxamide Groups Or Plural C=o Groups Bonded Directly To The Same Nitrogen Patents (Class 514/616)
-
Publication number: 20130184341Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an electrophile containing biocide, and its use for the control of microorganisms in aqueous and water-containing systems.Type: ApplicationFiled: September 30, 2010Publication date: July 18, 2013Applicant: DOW GLOBAL TECHNOLOGIES INC.Inventors: Bei Yin, Freddie L. Singleton
-
Publication number: 20130184343Abstract: A compound of formula (I): wherein A1, A2, A3, A4, R1, R2, G1, G2, Q1 and Q2 are as defined in claim 1; or salts or N-oxides thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and control insect, acarine, mollusc and nematode pests.Type: ApplicationFiled: March 4, 2013Publication date: July 18, 2013Applicants: Syngenta Crop Protection LLC, Syngenta Participations AGInventor: Syngenta Participations AG
-
Publication number: 20130184345Abstract: The present invention provides bis- and tris-benzamide compounds in the treatment of breast, brain and ovarian cancers.Type: ApplicationFiled: November 21, 2012Publication date: July 18, 2013Applicant: The Board of Regents of the University of Texas SystemInventor: The Board of Regents of the University of Texas S
-
Publication number: 20130184222Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.Type: ApplicationFiled: July 15, 2011Publication date: July 18, 2013Applicant: AGIOS PHARMACEUTICALS, INCInventors: Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey Saunders, Jeremy Travins, Shunqi Yan
-
Patent number: 8487131Abstract: A compound of Formula I: or a pharmaceutically acceptable salt thereof is disclosed. In addition, pharmaceutical compositions thereof, methods for preparing and methods for using this compound or composition for treating a variety of diseases, including cancer and inflammation are also provided.Type: GrantFiled: December 3, 2010Date of Patent: July 16, 2013Assignee: Sanford-Burnham Medical Research InstituteInventor: Maurizio Pellecchia
-
Patent number: 8487130Abstract: Described is a new cooling agent represented by Structure I and compositions with known coolers having cooling properties and the application of Structure I in foodstuffs and chewing gum:Type: GrantFiled: February 25, 2011Date of Patent: July 16, 2013Assignee: International Flavors & Fragrances Inc.Inventors: Arkadiusz Kazimierski, Mark L. Dewis
-
Publication number: 20130178446Abstract: The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to alleviate oily skin.Type: ApplicationFiled: March 4, 2013Publication date: July 11, 2013Applicant: Medicis Pharmaceutical CorporationInventors: Catherine R. Kostlan, Raj Neil Raheja, Meera Tugnait, Kimberly Wade
-
Patent number: 8481571Abstract: A method of treating coronavirus infection. The method includes administering to a subject suffering from or being at risk of suffering from such infection an effective amount of a compound of formula (I). Each variable in this formula is defined in the specification.Type: GrantFiled: May 3, 2005Date of Patent: July 9, 2013Assignee: Academia SinicaInventors: Chi-Huey Wong, Chung-Yi Wu, Jia-Tsrong Jan
-
Publication number: 20130172388Abstract: Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: wherein: R1 and R2 are independently H, alkyl, or alkenyl; R3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R4 and R5 are independently a bond, alkylenyl, or alkenylenyl; each R6 and R7 is independently selected from the group consisting of OH, F, Cl, Br, I, (C1-C6)alkyl, alkoxy, amino, COOH, CONH2, SO3H, PO3H2, CN, SH, NO2 and CF3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.Type: ApplicationFiled: December 14, 2012Publication date: July 4, 2013Applicant: University of Pittsburgh -- Of the Commonwealth System of Higher EducationInventor: University of Pittsburgh -- Of the Commonwealth System of Higher Education
-
Publication number: 20130172421Abstract: The use of Kukoamine A and Kukoamine B in the preparation of drugs for the prevention and treatment of sepsis and autoimmune disease is disclosed. Bacterial endotoxin/lipopolysaccaride (LPS) and unmethylated DNA (CpG DNA) of bacteria, the major pathogen-associated molecular patterns in sepsis and autoimmune disease, are specifically targeted, while the disclosed use directionally isolates lead compounds from traditional Chinese medicine. These measures can overcome the major defects of uncertainty of pharmacological material basis and drug targets of extracts and constituents of traditional Chinese medicine. The disclosed use can help in developing a safe, effective and quality controllable drug for prevention and treatment of sepsis and autoimmune disease so as to help solve the present lack of effective drugs in clinical treatment.Type: ApplicationFiled: March 21, 2011Publication date: July 4, 2013Applicants: Tianjin Chasesun Pharmaceutical Co., Ltd., The First Affiliated Hospital, Third Military Medical University, PLAInventors: Jiang Zheng, Xin Liu, Xinchuan Zheng, Hong Zhou, Hongwei Cao, Ning Wang, Yongling Lu
-
Publication number: 20130165443Abstract: Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted phenyl or optionally substituted pyridinyl, and R2, R3, R4, R5, R6, R7, R8 and R9 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.Type: ApplicationFiled: August 23, 2012Publication date: June 27, 2013Inventors: Chris Allen Broka, Ronald Charles Hawley
-
Publication number: 20130164228Abstract: Described herein are compositions for topical use comprising an antibacterially effective concentration of a gallate or gallamide compound which is a polysubstituted cycloalkyl or heterocycloalkyl wherein the substituents are selected from hydroxy, hydroxymethyl, fluoro, chloro, amino, nitro, or a moiety of formula -X-(CO)-(3,4,5-trihydroxyphenyl), wherein X is selected from O and NH, provided that the substituents comprise at least two moieties of formula -X-(CO)-(3,4,5-trihydroxyphenyl) attached to adjacent carbons in free or in orally or topically acceptable salt form, as well as methods of making and using the same.Type: ApplicationFiled: December 21, 2011Publication date: June 27, 2013Applicant: Colgate-Palmolive CompanyInventors: Stanislav Jaracz, Guofeng Xu, Steven Miller, Leonora Leigh, Guillaume Picquet, Laurence Du-Thumm
-
Publication number: 20130158112Abstract: A pharmaceutical composition for inhibiting amyloid beta peptide in a subject includes a compound having the formula (I): where M is selected from a substituted or unsubstituted alkyl, halo, alkoxy, aryl, cyclic, or heterocyclic group; p is an integer from 0-3; X1 is a 3-9 atoms in length linker connecting A and B; B is selected from a substituted or unsubstituted aryl, alkoxy or amine group; and a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier.Type: ApplicationFiled: June 20, 2012Publication date: June 20, 2013Inventors: Jonathan D. Smith, Enakshi Chakrabarti, Subrata Ghosh, Marti Sayre, Gregory Tochtrop
-
Patent number: 8466126Abstract: Compositions, kits and methods are provided for conditioning, revitalizing, volumizing or increasing the natural pigmentation of the hair, including hair on the scalp, eyelashes, eyebrows, mustache and beard, promoting healthy growth, and treating and preventing loss, thinning or miniaturization of hair due to aging, various genetic, pathological, radiation, chemotherapy, chemical treatment, environmental or other reasons.Type: GrantFiled: October 27, 2010Date of Patent: June 18, 2013Assignee: Jan Marini Skin Research, Inc.Inventor: Jan Marini
-
Patent number: 8466180Abstract: Novel compounds of formula (I): wherein A1, A2, A3, A4, R1, R2, G1, G2, Q1 and Q2 are as defined in claim 1; or salts or N-oxides thereof. Furthermore, the present invention relates to processes for preparing compounds of formula (I), to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and control insect, acarine, mollusc and nematode pests.Type: GrantFiled: September 7, 2007Date of Patent: June 18, 2013Assignee: Syngenta Crop Protection LLCInventors: Pierre Joseph Marcel Jung, Stephan Trah, Christopher Richard Ayles Godfrey, William Lutz, Peter Maienfisch, Werner Zambach
-
Publication number: 20130150442Abstract: The present invention includes bis- and tris-benzamide compounds that block AR signaling and have activity against prostate cancer. Uses for these compounds, and pharmaceutical compositions containing the same, also are provided.Type: ApplicationFiled: November 21, 2012Publication date: June 13, 2013Applicant: The Board of Regents of the University of Texas SystemInventor: The Board of Regents of the University of Texas S
-
Publication number: 20130150450Abstract: Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Forms A, B, and D, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Forms A, B, and D, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed.Type: ApplicationFiled: September 15, 2012Publication date: June 13, 2013Applicant: THE BROAD INSTITUTE, INC.Inventors: Edward Holson, Florence F. Wagner, G. Patrick Stahly
-
Patent number: 8455688Abstract: This invention provides the compound having the structure wherein n is 1-10; X is C—R11 or N, wherein R11 is H, OH, SH, F, Cl, SO2R7, NO2, trifluoromethyl, methoxy, or CO—R7, wherein R7 is alkyl, alkenyl, alkynyl, C3-C8 cycloalkyl, or aryl; Z is R2 is H or NR3R4, wherein R3 and R4 are each independently H, C1-C6 alkyl, or C3-C8 cycloalkyl; R5 is OH or SH; and R6, R12, R13, and R14 are each independently H, OH, SH, F, Cl, SO2R15, NO2, trifluoromethyl, methoxy, or CO—R15, wherein R15 is alkyl, alkenyl, alkynyl, C3-C8 cycloalkyl, or aryl, or a salt of the compound, which is useful in the treatment of tumors.Type: GrantFiled: March 21, 2012Date of Patent: June 4, 2013Assignee: Lixte Biotechnology, Inc.Inventors: John S. Kovach, Francis Johnson
-
Publication number: 20130137706Abstract: The present invention provides methods of inhibiting the growth of Mycobacterium species or treating an animal having a Mycobacterium infection (including multi-drug resistance strains and extensively drug resistant strains) by administering a compound of the invention, a salt thereof, or a composition comprising the same.Type: ApplicationFiled: October 23, 2012Publication date: May 30, 2013Applicant: POLYMEDIX, INC.Inventor: POLYMEDIX, INC.
-
Patent number: 8450525Abstract: Novel compounds of the general formula (I), having histone deacetylase (HDAC) inhibiting enzymatic activity, their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel compounds of the general formula (I). Also included is a method for treatment of cancer, psoriasis, proliferative conditions and conditions mediated by HDAC, in a mammal comprising administering an effective amount of a novel compound of formula (I).Type: GrantFiled: October 21, 2008Date of Patent: May 28, 2013Assignee: Orchid Chemicals & Pharmaceuticals LimitedInventors: Sridharan Rajagopal, Virendra Kachhadia, Thanasekaran Ponpandian, Abdul Raheem Keeri, Karnambaram Anandhan, Sriram Rajagopal, Rajendran Praveen, Prabhu Daivasigamani
-
Patent number: 8450373Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.Type: GrantFiled: July 27, 2011Date of Patent: May 28, 2013Assignee: Virobay, Inc.Inventors: Michael Graupe, John O. Link, Michael G. Roepel
-
Patent number: 8445534Abstract: This invention provides methods for treatment and inhibition of a male subject having an Androgen Decline in Aging Male (ADAM)-associated condition, for example sexual dysfunction, decreased sexual libido, erectile dysfunction, hypogonadism, sarcopenia, osteopenia, osteoporosis, an alteration in cognition and mood, depression, anemia, hair loss, obesity, muscle loss, dry eye, memory loss, benign prostate hyperplasia and/or prostate cancer, by administering to the subject a selective androgen receptor modulator (SARM) compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, pro-drug, polymorph, crystal, or any combination thereof.Type: GrantFiled: December 7, 2009Date of Patent: May 21, 2013Assignee: University of Tennessee Research FoundationInventors: James T. Dalton, Duane D. Miller, Donghua Yin, Yali He
-
Patent number: 8445538Abstract: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.Type: GrantFiled: December 9, 2009Date of Patent: May 21, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Songnian Lin, Xibin Liao, Roman Kats-Kagan, John E. Stelmach, Emma R. Parmee
-
Publication number: 20130123356Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof,Type: ApplicationFiled: October 18, 2012Publication date: May 16, 2013Applicant: UNIVERSITY COLLEGE LONDONInventors: Masahiro Okuyama, David Selwood, Cristina Visintin, David Baker, Gareth Pryce
-
Patent number: 8440861Abstract: The invention relates to solid forms of the anti-epileptic agent lacosamide (I). The invention also relates to mixtures of solid forms of lacosamide. The invention further relates to mixtures of lacosamide enantiomers crystallized in a conglomerate Form and the use thereof in providing enantiomerically enriched lacosamide, preferably lacosamide enriched with the (R)-enantiomer of lacosamide.Type: GrantFiled: August 5, 2010Date of Patent: May 14, 2013Assignee: Medichem, S.A.Inventors: Ernesto Duran Lopez, Monica Benito Velez, Jordi Bosch i Lladó
-
Publication number: 20130115249Abstract: The osmotic devices of the present invention contain a unitary core comprising a salt of amantadine and an osmotic salt, wherein the two salts have an ion in common. The release rate of the amantadine is a sigmoidal release. The osmotic device includes a semipermeable membrane having a controlled porosity that can be adapted as needed to cooperate with the osmotic salt in providing a predetermined drug release profile. The osmotic salt need not be coated and it is in admixture with the amantadine salt. The osmotic device further includes a drug-containing coat external to the semipermeable membrane. The osmotic device can include one or more additional drugs in the core and/or the drug-containing coat.Type: ApplicationFiled: July 18, 2012Publication date: May 9, 2013Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFTInventors: Juan A. VERGEZ, Joaquina FAOUR, Ana C. PASTINI, Guido S. BIGATTI, Glenn A. MEYER, Ethel C. FELEDER, Marcelo A. RICCI, Marcelo A. COPPARI, Marcelo F. BEFUMO
-
Patent number: 8436207Abstract: Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, or NHSO2X, wherein X is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, heterocycle, or substituted heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.Type: GrantFiled: September 21, 2011Date of Patent: May 7, 2013Assignee: Burnham Institute for Medical ResearchInventor: Maurizio Pellecchia
-
Publication number: 20130109698Abstract: The present invention includes a method of inhibiting, suppressing or preventing retroviral infection in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising one or more of the compounds of the invention.Type: ApplicationFiled: April 25, 2011Publication date: May 2, 2013Inventor: Simon Cocklin
-
Publication number: 20130109752Abstract: The present invention is correlated with a derivative of 18?-glycyrrhetinic acid apt to suppressing cancer cells, which is selected from a group comprising of structure I and structure II: wherein residue R1 is selected from one of CH3 and CH2C6H5, residue R2 is selected from one of COOCH3, COOCH2CH3, COOCH(CH3)2, CONHCH2CH3, CONHCH2CH2CH3, and CONHCH2(CH3)2, and residue R3 is selected from one of COOCH2CH3, COOCH(CH3)2, CONHCH2CH3, CONHCH2CH2CH3, and CONHCH2(CH3)2.Type: ApplicationFiled: March 14, 2012Publication date: May 2, 2013Inventors: Chun-Nan Lin, Kai-Wei Lin, A-Mei Huang, Tzyh-Chyuan Hour, Shyh-Chyun Yang, Yeong-Shiau Pu, Jan-Gowth Chang
-
Publication number: 20130102538Abstract: The present invention relates to a method for treating an individual having Alzheimer's Disease by using pharmacological chaperones that bind presenelin and thereby increase ?-secretase activity.Type: ApplicationFiled: May 4, 2011Publication date: April 25, 2013Applicant: AMICUS THERAPEUTICS, INC.Inventors: Brandon Wustman, Anthony Stevens
-
Publication number: 20130102677Abstract: Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Forms A, B, and D, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Forms A, B, and D, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed.Type: ApplicationFiled: September 15, 2012Publication date: April 25, 2013Applicant: THE BROAD INSTITUTE, INC.Inventors: Edward Holson, Florence F. Wagner, G. Patrick Stahly
-
Patent number: 8426463Abstract: The present invention pertains generally to the field of coolants and medical therapy. More particularly, the present invention relates to certain anti-nociceptive agents, such as [((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester, that are potent and long-acting and selectively cooling for non-keratinized epithelial tissues as compared to keratinized epithelial tissues, and are useful, for example, for the treatment of (e.g., the alleviation of symptoms of; the amelioration of) sensory discomfort of non-keratinized stratified epithelial (NKSE) tissue; and so for treatment of: sensory discomfort of an ocular surface, an eyelid, a margin of an eyelid, an anterior part of an eyeball, a conjunctiva, a lachrymal system, a pre-corneal film, or a cornea, a lining of the oral cavity, an internal portion of the lips, a pharyngeal surface, an esophageal surface, or an anogenital surface; eye discomfort, e.g.Type: GrantFiled: April 4, 2011Date of Patent: April 23, 2013Inventor: Edward T. Wei
-
Publication number: 20130095110Abstract: The present invention is directed to KIAA1199, which is a novel factor involved in decomposition of hyaluronic acid, and to use thereof. More specifically, the invention is directed to a hyaluronic acid decomposition-promoting agent containing the KIAA1199 gene and a protein encoded by the gene; to a hyaluronic acid decomposition-inhibiting agent characterized by inhibiting the activity or expression thereof (including an siRNA or a monoclonal antibody); and to a method for screening a novel hyaluronic acid decomposition-controlling agent, in which the method contains employing the expression of KIAA1199 as an index.Type: ApplicationFiled: June 3, 2011Publication date: April 18, 2013Applicant: KAO CORPORATIONInventors: Hiroyuki Yoshida, Shintaro Inoue, Shingo Sakai, Aya Nagaoka
-
Publication number: 20130096092Abstract: Disclosed are inhibitors of retroviral growth of formula (I), that are useful in treatment of retroviral infections such as HIV. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound or salt of the invention, a method for inactivating a virus, a method for dissociating a metal ion from a zinc finger-containing protein, and a method for inhibiting the transmission of a virus.Type: ApplicationFiled: June 10, 2011Publication date: April 18, 2013Applicants: Health and Human ServicesInventors: Daniel Appella, Ettore Appella, John K. Inman, Lisa M. Miller Jenkins, Ryo Hayashi, Deyun Wang
-
Patent number: 8409595Abstract: The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to alleviate oily skin.Type: GrantFiled: September 29, 2009Date of Patent: April 2, 2013Assignee: Medicis Pharmaceutical CorporationInventors: Catherine R. Kostlan, Raj Neil Raheja, Meera Tugnait, Kimberly Wade
-
Publication number: 20130071490Abstract: Embodiments disclosed herein relate to improved X-ray contrast media compositions and methods of using the same for treating symptoms related to allergic reactions, inflammatory conditions, symptoms of the common cold and certain cancers.Type: ApplicationFiled: November 18, 2011Publication date: March 21, 2013Inventor: Elliott C. Lasser
-
Publication number: 20130071328Abstract: This invention discloses a series of novel propynoic acid carbamoyl methyl-amides (PACMAs), methods for synthesizing the PACMAs and pharmaceutical compositions containing the PACMAs. These novel compounds and compositions show cytotoxicity in cancer cells and are useful as lead compounds for anti-cancer drugs or pharmaceutical agents. This invention also discloses treatment methods that uses the PACMAs and pharmaceutical compositions as well as methods for promoting the release and nuclear localization of the transcription factor Nrf2.Type: ApplicationFiled: March 22, 2012Publication date: March 21, 2013Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: Nouri NEAMATI, Nicos A. PETASIS, Roppei YAMADA
-
Publication number: 20130071353Abstract: Inhibitors of retroviral propagation, methods of treatment and prevention of retroviral infections using the inhibitors, and pharmaceutical compositions including the inhibitors, are disclosed.Type: ApplicationFiled: March 14, 2011Publication date: March 21, 2013Applicant: TRANA DISCOVERY, INCInventors: Richard H. Guenther, Jerzy R. Szewczyk
-
Patent number: 8399437Abstract: Methods for using tetracycline compounds for the treatment of spinal muscular atrophy are described.Type: GrantFiled: May 3, 2011Date of Patent: March 19, 2013Assignee: Paratek Pharmaceuticals, Inc.Inventors: Joel Berniac, Todd Bowser, Michael P. Draper, Stuart B. Levy, Mark L. Nelson
-
Publication number: 20130065308Abstract: The invention provides a cationic lipid comprising: (i) one head group, comprising one or more amino acids, in which at least one amino acid has a side chain that comprises a cationic moiety or a cationic precursor; (ii) a linking moiety of formula (5): —(HNR5)2NC(O)R3C(O)—??(5), wherein: each R5 is independently an optionally substituted C1-4 alkylene moiety; and R3 is an optionally substituted alkylene or alkenylene moiety; and (iii) two lipophilic moieties, wherein the head group and each of the lipophilic moieties are connected to the linking moiety through amide linkages.Type: ApplicationFiled: May 17, 2011Publication date: March 14, 2013Applicant: The University Court of the University of EdinburghInventors: Asier Unciti-Broceta, Aleksandra Liberska, Mark Bradley
-
Publication number: 20130065963Abstract: The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.Type: ApplicationFiled: July 17, 2012Publication date: March 14, 2013Applicant: Georgetown UniversityInventors: Alan P. Kozikowski, Anatoly Dritschilo, Mira Jung, Pavel A. Petukhov, Bin Chen
-
Publication number: 20130065964Abstract: The present invention relates to a type of peritoneal dialysis solution that comprises aliskiren or any of its derivatives, at least one electrolyte, at least one buffer solution and at least one osmotic agent. This enables toxicity reduction in these habitually used peritoneal dialysis solutions with respect to peritoneal mesothelial cells. On the other hand, the present invention relates to the use of these types of solutions in processes requiring peritoneal dialysis, as in the case of chronic renal failure.Type: ApplicationFiled: March 4, 2011Publication date: March 14, 2013Applicant: UNIVERSIDAD DE CASTILLA LA MANCHAInventors: Valentín Ceña Callejo, Francisco Carlos Pérez Martínez, Juan Pérez Martínez, Carmen Gómez Roldán, Agustín Ortega Cerrato, Francisco Llamas Fuentes
-
Novel 1, 2-Disubstituted Amido-anthraquinone Derivatives, Preparation Method and application thereof
Publication number: 20130059862Abstract: The invention provides a series of novel 1,2-disubstituted amido-anthraquinone derivatives. Further, the invention also provides the preparation method and application of said derivatives, said application comprises: said derivatives with therapeutically effective amount are prepared into pharmaceutical compositions for inhibition of cancer cell growth, further treating cancer.Type: ApplicationFiled: August 1, 2012Publication date: March 7, 2013Inventor: Hsu-Shan HUANG -
Publication number: 20130059911Abstract: There are provided various polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds can be useful as cancer chemopreventive agents, cancer treating agent, inhibiting tumor growth or cell proliferation, reducing tumor growth or as radioenhencers for radiotherapy of cancer.Type: ApplicationFiled: November 1, 2012Publication date: March 7, 2013Applicant: Centre de Recherche sur les Biotechnologies MarinesInventor: Centre de Recherche sur les Biotechnologies Mari
-
Publication number: 20130059801Abstract: The invention relates to fatty acid amides; compositions comprising an effective amount of a fatty acid amide; and methods for treating or preventing cancer, a metabolic disease or a neurodegenerative disease comprising the administration of an effective amount of a fatty acid amide.Type: ApplicationFiled: August 31, 2012Publication date: March 7, 2013Applicant: Catabasis Pharmaceuticals, Inc.Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu, Amal Ting
-
Patent number: 8389766Abstract: A compound of formula (I): wherein A1, A2, A3, A4, R1, R2, G1, G2, Q1 and Q2 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and control insect, acarine, mollusc and nematode pests.Type: GrantFiled: December 12, 2007Date of Patent: March 5, 2013Assignee: Syngenta Crop Protection LLCInventors: Pierre Jung, Christopher Richard Syles Godfrey, William Lutz, Peter Maienfisch, Andre Stoller, Werner Zambach
-
Patent number: 8389519Abstract: The present invention provides adamantyl-diamide derivatives of formula (I): wherein R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods using the same.Type: GrantFiled: May 15, 2012Date of Patent: March 5, 2013Assignee: H. Lundbeck A/SInventors: Hermogenes N. Jimenez, Guiying Li, Dario Doller, Michel Grenon, Andrew D. White, Gil Ma, Maojun Guo
-
Publication number: 20130053417Abstract: The invention provides a compound that is a CETP activity inhibitor. The compound can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity, the invention also provides for the use of the compound to prevent or treat atherosclerosis or hyperlipidemia.Type: ApplicationFiled: March 21, 2012Publication date: February 28, 2013Applicant: JAPAN TOBACCO INC.Inventors: Hisashi Shinkai, Kimiya Maeda, Hiroshi Okamoto
-
Publication number: 20130053412Abstract: The invention relates to cyclopentanecarboxamide derivatives of formula 1, to their use as Fatty Acid Synthase inhibitors, to methods for their therapeutic use and to pharmaceutical compositions containing them, wherein R1, R2, R3, LO, W, AR1, n are as defined in claim 1.Type: ApplicationFiled: October 15, 2010Publication date: February 28, 2013Applicant: Boehringer Ingelheim International GmbHInventors: Joerg Kley, Bradford S. Hamilton, Juergen Mack, Norbert Redemann, Corinna Schoelch
-
Publication number: 20130045982Abstract: Disclosed are benzamide derivatives useful in slowing the expansion of cancer cells including the killing of cancer cells and in the treatment of cancer.Type: ApplicationFiled: December 17, 2010Publication date: February 21, 2013Applicant: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTEInventors: Tong Wang, Stephen Gately